Taribavirin

Taribavirin

SCHEMBL40670

N=C(N)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 4/20 1.00
LMNA P02545 4/20 0.76
SMN1; SMN2 Q16637 4/20 0.76
ALDH1A1 P00352 3/20 0.76
TSHR P16473 2/20 0.76
THPO P40225 2/20 0.76
PMP22 Q01453 2/20 0.76
ADORA1 P30542 2/20 0.76
GLA P06280 1/20 0.76
EIF4E P06730 1/20 0.76
CYP3A4 P08684 1/20 0.76
TOP1 P11387 1/20 0.76
KDM4E B2RXH2 2/20 0.47
HTT P42858 2/20 0.47
BLM P54132 2/20 0.47
TP53 P04637 2/20 0.47
MAPT P10636 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
GAA P10253 1/20 0.47
GMNN O75496 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Taribavirin SCHEMBL3868643 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR
Taribavirin SCHEMBL2619250 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR
Taribavirin SCHEMBL12758161 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR
Taribavirin SCHEMBL3307695 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR
Taribavirin SCHEMBL3307685 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR
Taribavirin SCHEMBL4967368 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR
Taribavirin SCHEMBL16330745 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR
Taribavirin SCHEMBL6981526 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR
Taribavirin SCHEMBL2631656 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR
Taribavirin SCHEMBL18735565 1.00 PNP (1.00) PNPLMNASMN1; SMN2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2755 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144879-A1 ANTI-VIRAL AND HEPATIC-TARGETED DRUGS AI-BIOPHARMA (FR) 2026-05-28 US claimed
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
EP-3790536-B1 NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS KARLSRUHER INST TECHNOLOGIE (DE) 2026-04-22 EP claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4673568-A1 MICROBIAL BIOMARKERS IN TRANSPLANTATION AND RELATED METHODS Karius, Inc. (US) 2026-01-07 EP claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4566670-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2025-06-11 EP claimed
US-6680292-B1 STIMULATION OF NEURONAL SURVIVAL, PROLIFERATION AND NEURITE ELONGATION THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2004-01-20 US claimed
CN-1447692-A Methods of drug delivery to hepatocytes and treatment of flavivirus infections ICN PHARMACEUTICALS (US) 2003-10-08 CN claimed
EP-1313469-A1 METHODS OF DRUG DELIVERY TO HEPATOCYTES AND TREATMENT OF FLAVIVIRIDAE INFECTIONS Ribapharm, Inc. (US) 2003-05-28 EP claimed
WO-2002015904-B1 METHODS OF DRUG DELIVERY TO HEPATOCYTES AND TREATMENT OF FLAVIVIRIDAE INFECTIONS ICN PHARMACEUTICALS (US) 2002-07-04 WO claimed
WO-2002015904-A1 METHODS OF DRUG DELIVERY TO HEPATOCYTES AND TREATMENT OF FLAVIVIRIDAE INFECTIONS RIBAPHARM, INC. (US) 2002-02-28 WO claimed
WO-2000030656-A9 NEURON STIMULATION BY RIBAVIRIN, AND ANALOGS THEREOF SALK INST FOR BIOLOGICAL STUDI (US) 2001-12-13 WO claimed
WO-2000030656-A1 NEURON STIMULATION BY RIBAVIRIN, AND ANALOGS THEREOF THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2000-06-02 WO claimed
EP-0374096-B1 COMBINATION THERAPY INVOLVING 2',3'-DIDEOXYPURINE NUCLEOSIDE AND AN INHIBITOR OF PURINE NUCLEOSIDE PHOSPHORYLASE, AND ITS COMPOSITIONS CIBA-GEIGY AG (CH) 1992-12-02 EP claimed
EP-0374096-A1 Combination therapy involving 2',3'-dideoxypurine nucleoside and an inhibitor of purine nucleoside phosphorylase, and its compositions CIBA-GEIGY AG (CH) 1990-06-20 EP claimed
US-RE29835-E PHARMACEUTICAL ICN PHARMACEUTICALS (US) 1978-11-14 US claimed